3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
1
Prostate Cancer Metastatic
1
Interventions
enzalutamide
2
cabazitaxel
2
Prednisone
2
Androgen Antagonists
2
fludrocortisone acetate
1
darolutamide
1
XRP6258
1
Radiosurgery
1
Pluvicto
1
Lutetium-177
1
Lutetium
1
Lenograstim
1
Hydrocortisone
1
Granulocyte Colony-Stimulating Factor
1
Docetaxel
1
Dexamethasone
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Prostate Cancer Metastatic
×
fludrocortisone acetate
×
Clear all
NCT06136624
2026-05-05
OMAHA-003
Merck Sharp & Dohme LLC
Phase 3
Recruiting
1,310 enrolled